Compare CTXR & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTXR | HSCS |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.8M |
| IPO Year | 2010 | 2022 |
| Metric | CTXR | HSCS |
|---|---|---|
| Price | $0.51 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 253.3K | 75.5K |
| Earning Date | 12-22-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.38 | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | $104.18 | $18,321.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $1.63 |
| 52 Week High | $1.54 | $5.25 |
| Indicator | CTXR | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 27.72 |
| Support Level | $0.47 | N/A |
| Resistance Level | $0.63 | $2.18 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 22.42 | 0.00 |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.